Absorption Systems has acquired Perry Scientific, Inc., an in vivo toxicology and pharmacokinetics testing company located in San Diego, CA. Perry’s research services include testing for toxicology, medical devices, preclinical models and CNS pharmacology.

In addition to routine preclinical pharmacokinetics testing, Absorption Systems will now conduct GLP studies in the San Diego testing facility, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

“The acquisition of Perry Scientific furthers our mission to efficiently move clients from the early stages of drug discovery testing for ADME and pharmacokinetics through the definitive safety and toxicology testing necessary for new drug and device submissions,” commented Patrick M. Dentinger, president and chief executive officer of Absorption Systems. “By offering a full range of tests, we will be able to design and perform studies that will get clients to the point of submission to the FDA as quickly as possible.”

“Joining forces with Absorption Systems is a natural step in our growth because our respective businesses are entirely complementary,” said Andrew Perry M.D., Ph.D., founder of Perry Scientific. Now we can offer our customers the convenience and accuracy of having an entire preclinical testing package performed at a single facility—the combined company offers all the services needed to move a new drug from the benchtop to the clinic.”